Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10717MR)

This product GTTS-WQ10717MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10717MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3606MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ5084MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ1040MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ13321MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ3156MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ8988MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ15543MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ6515MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW